InflaRx (NASDAQ: IFRX) cuts Q1 loss but flags going concern risk

Rhea-AI Filing Summary

InflaRx N.V. reported a Q1 2026 net loss of €5.6 million, improving from a €8.3 million loss a year earlier, as it restructures and pivots resources toward its oral C5aR inhibitor izicopan.

Operating expenses fell to €7.5 million from €13.5 million, driven by sharply lower sales and marketing and reduced research and development and general and administrative costs, including lower share-based payments. GOHIBIC (vilobelimab) U.S. sales were discontinued, so the company recorded no revenue or cost of sales in the quarter.

Net financial income of €1.6 million reflected warrant revaluation gains and favorable foreign exchange. Cash and cash equivalents were €15.0 million and marketable securities €24.7 million, for total funds of about €39.7 million. Management believes this will fund operations into 2027, yet the company states that a material uncertainty exists that may cast significant doubt on its ability to continue as a going concern, given ongoing losses and planned clinical development spending.

Positive

• None.

Negative

• Going concern uncertainty: Management states that ongoing operating losses and planned clinical spending create a material uncertainty that may cast significant doubt on InflaRx’s ability to continue as a going concern, despite current funding expected to last into 2027.

Insights

Biopharma equity analyst

Loss narrows and costs fall, but going concern risk remains highlighted.

InflaRx reduced its Q1 2026 net loss to €5.6M from €8.3M as it wound down GOHIBIC commercialization and reoriented spending toward its oral C5aR inhibitor izicopan. Operating expenses declined to €7.5M, mainly from lower marketing, R&D and G&A, including reduced share-based compensation.

Available funds totaled about €39.7M at March 31, 2026, and the company states this should finance its current plan into 2027. However, management explicitly notes a material uncertainty that may cast significant doubt on its ability to continue as a going concern, reflecting ongoing losses and future trial funding needs.

The strategy now centers on advancing izicopan in indications such as HS, CSU, ANCA-associated vasculitis and kidney diseases, while vilobelimab moves away from near-term commercial focus. Future disclosures on Phase 2b HS trial design acceptance and any additional financing steps will be key to understanding execution under this constrained capital position.

Key Figures

Net loss: €5,592,649 Net loss prior year: €8,314,027 Total operating expenses: €7,456,062 +5 more

8 metrics

Net loss €5,592,649 For the three months ended March 31, 2026

Net loss prior year €8,314,027 For the three months ended March 31, 2025

Total operating expenses €7,456,062 For the three months ended March 31, 2026

Research and development expenses €4,170,546 For the three months ended March 31, 2026

General and administrative expenses €3,177,444 For the three months ended March 31, 2026

Cash and cash equivalents €14,993,792 As of March 31, 2026

Marketable securities €24,690,348 Current financial assets as of March 31, 2026

Net cash used in operating activities €7,392,345 For the three months ended March 31, 2026

Key Terms

going concern, pre-funded warrants, at-the-market program, research allowances, +2 more

6 terms

going concern financial

"a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

pre-funded warrants financial

"the Company issued 6,750,000 pre-funded warrants to certain investors in the context of a public offering"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

at-the-market program financial

"a prospectus supplement with the SEC relating to an at-the-market program providing for the sale of up to $75.0 million"

An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.

research allowances financial

"research allowances recognized in connection with eligible research and development expenditures incurred during the period"

Phase 2a clinical study technical

"we reported positive data from a Phase 2a clinical study in HS and CSU patients"

C5a receptor (C5aR1) technical

"izicopan, which is an orally administered, small-molecule inhibitor of C5aR1"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-38283

InflaRx N.V.

(Translation of registrant's name into English)

Winzerlaer Str. 2

07745 Jena, Germany

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

Exhibits 99.1 and 99.2 to this report on Form 6-K (this “Report”) shall be deemed to be incorporated by reference into (i) the registration statements on Form S-8 (File No. 333-221656 and 333-240185) and (ii) the registration statement on Form F-3 (File No. 333-273058) of InflaRx N.V. and to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.	Description
99.1	InflaRx N.V. Unaudited Condensed Consolidated Financial Statements as of and for the Three Months Ended March 31, 2026
99.2	InflaRx N.V. Management’s Discussion and Analysis of Financial Condition and Results of Operations

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INFLARX N.V.
Date: May 6, 2026	By:	/s/ Niels Riedemann
	Name:	Niels Riedemann
	Title:	Chief Executive Officer

Exhibit 99.1

INFLARX N.V.

UNAUDITED CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS – March 31, 2026

These unaudited condensed financial statements are consolidated financial statements for the group consisting of InflaRx N.V. and its wholly-owned subsidiaries InflaRx GmbH, Jena, Germany, and InflaRx Pharmaceuticals Inc., Ann Arbor, Michigan, United States (together, the “Group”). The financial statements are presented in euros (€).

InflaRx N.V. is a company limited by shares, incorporated and domiciled in Amsterdam, The Netherlands.

Its registered office and principal place of business is in Germany, 07745 Jena, Winzerlaer Str. 2

F-1

Index to unaudited condensed consolidated financial statements

for the three months ended March 31, 2026

Unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025				F-3
Unaudited condensed consolidated statements of financial position as of March 31, 2026 and December 31, 2025				F-4
Unaudited condensed consolidated statements of changes in shareholders’ equity for the three months ended March 31, 2026 and 2025				F-5
Unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025				F-6
Notes to the unaudited condensed consolidated financial statements				F-7
	1.		Summary of significant accounting policies and other disclosures	F-7
		a)	Reporting entity and the Group’s structure	F-7
		b)	Basis of preparation	F-7
	2.		Revenues	F-8
	3.		Cost of sales	F-8
	4.		Sales and marketing expenses	F-8
	5.		Research and development expenses	F-8
	6.		General and administrative expenses	F-8
	7.		Other income	F-8
	8.		Net financial result	F-9
	9.		Inventory	F-9
	10.		Other assets	F-9
	11.		Tax receivables	F-10
	12.		Financial assets and financial liabilities	F-10
	13.		Trade payables and other accrued liabilities	F-11
	14.		Cash and cash equivalents	F-11
	15.		Equity	F-11
	16.		Share-based payments	F-12
		a)	Equity settled share-based payment arrangements	F-12
		b)	Share-based payment expense recognized	F-13
		c)	Share options exercised	F-13
	17.		Protective foundation	F-13
	18.		Subsequent events	F-13

F-2

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025

						For the three months ended March 31,
		Note				2026 (unaudited)				2025 (unaudited)
						(in €, except for share data)
Revenues			2				—				—
Cost of sales			3				—				(9,291	)
Gross profit (loss)							—				(9,291	)
Sales and marketing expenses			4				(108,072	)			(1,457,978	)
Research and development expenses			5				(4,170,546	)			(7,016,336	)
General and administrative expenses			6				(3,177,444	)			(5,062,605	)
Other income			7				247,978				541,098
Other expenses							(66	)			(26	)
Operating result							(7,208,150	)			(13,005,139	)
Finance income			8				334,768				493,764
Finance expenses			8				(14,809	)			(4,086	)
Foreign exchange result			8				492,382				(1,908,829	)
Other financial result			8				803,160				6,110,264
Income taxes							—				—
Income (loss) for the period							(5,592,649	)			(8,314,027	)
Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods:
Exchange differences on translation of foreign currency							(15,026	)			(150,667	)
Total comprehensive income (loss)							(5,607,675	)			(8,464,694	)
Share information
Weighted average number of shares outstanding							72,292,859				63,312,911
Income (loss) per share (basic/diluted)							(0.08	)			(0.13	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-3

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of financial position as of March 31, 2026 and December 31, 2025

		Note				March 31, 2026 (unaudited)				December 31, 2025
						(in €)
ASSETS
Non-current assets
Property and equipment							278,775				289,317
Right-of-use assets							791,173				861,667
Intangible assets							45,597				42,255
Other assets			10				139,192				151,198
Financial assets			12				237,459				237,373
Total non-current assets							1,492,196				1,581,810
Current assets
Current other assets			10				3,213,773				3,261,038
Other assets from government grants and research allowance			10				2,732,817				2,487,763
Tax receivables			11				1,650,338				1,428,428
Financial assets			12				24,806,894				30,435,088
Cash and cash equivalents			14				14,993,792				16,022,171
Total current assets							47,397,615				53,634,487
TOTAL ASSETS							48,889,811				55,216,297
EQUITY AND LIABILITIES
Equity
Issued capital			15				8,675,143				8,675,143
Share premium							354,975,760				354,975,760
Other capital reserves							49,501,597				48,560,500
Accumulated deficit							(383,418,650	)			(377,826,001	)
Other components of equity							7,156,353				7,171,379
Total equity							36,890,203				41,556,781
Non-current liabilities
Lease liabilities							571,737				640,973
Other liabilities			13				36,877				36,877
Total non-current liabilities							608,614				677,850
Current liabilities
Trade and other payables			12				4,845,138				5,399,383
Lease liabilities							251,291				256,943
Employee benefits							655,974				1,164,259
Liabilities to warrant holders							5,250,652				5,802,128
Other liabilities			13				387,938				358,954
Total current liabilities							11,390,994				12,981,666
Total Liabilities							11,999,608				13,659,516
TOTAL EQUITY AND LIABILITIES							48,889,811				55,216,297

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-4

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of changes in shareholders’ equity for the three months ended March 31, 2026 and 2025

(in €, except for share data)		Note				Shares outstanding				Issued capital				Share premium				Other capital reserves				Accumulated deficit				Other compo- nents of equity				Total equity
Balance as of January 1, 2026							72,292,859				8,675,143				354,975,760				48,560,500				(377,826,001	)			7,171,379				41,556,781
Loss for the period							—				—				—				—				(5,592,649	)			—				(5,592,649	)
Exchange differences on translation of foreign currency							—				—				—				—				—				(15,026	)			(15,026	)
Total comprehensive loss							—				—				—				—				(5,592,649	)			(15,026	)			(5,607,675	)
Equity-settled share-based payments			16				—				—				—				941,097				—				—				941,097
Balance as of March 31, 2026							72,292,859				8,675,143				354,975,760				49,501,597				(383,418,650	)			7,156,353				36,890,203
Balance as of January 1, 2025							59,351,710				7,122,205				334,929,685				44,115,861				(332,192,221	)			7,440,510				61,416,039
Loss for the period							—				—				—				—				(8,314,027	)			—				(8,314,027	)
Exchange differences on translation of foreign currency							—				—				—				—				—				(150,667	)			(150,667	)
Total comprehensive loss							—				—				—				—				(8,314,027	)			(150,667	)			(8,464,694	)
Issuance of common shares							8,395,420				1,007,450				15,136,235				—				—				—				16,143,687
Transaction costs							—				—				(1,109,330	)			—				—				—				(1,109,330	)
Equity-settled share-based payments			16				—				—				—				2,480,006				—				—				2,480,006
Balance as of March 31, 2025							67,747,130				8,129,656				348,956,590				46,595,867				(340,506,248	)			7,289,843				70,465,708

*unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-5

InflaRx N.V. and subsidiaries

Unaudited condensed consolidated statements of cash flows for the three months ended March 31, 2026 and 2025

						For the three months ended March 31,
		Note				2026 (unaudited)				2025 (unaudited)
						(in €)
Operating activities
Loss for the period							(5,592,649	)			(8,314,027	)
Adjustments for:
Depreciation & amortization of property and equipment, right-of-use assets and intangible assets							87,182				113,801
Net finance income			8				(1,615,501	)			(4,691,112	)
Share-based payment expense			16				941,097				2,480,006
Net foreign exchange differences and other adjustments							(74,236	)			972,608
Changes in:
Other assets from government grants and research allowances							(245,055	)			(532,860	)
Other assets and trade receivables			10				(162,639	)			(389,188	)
Employee benefits							(508,285	)			(1,350,189	)
Other liabilities			13				28,984				46,295
Trade and other payables			13				(554,245	)			(3,027,828	)
Inventories			9				—				2,295
Interest received			10				318,130				678,717
Interest paid							(15,130	)			(4,191	)
Net cash used in operating activities							(7,392,345	)			(14,015,672	)
Investing activities
Purchase of intangible assets, property and equipment							(9,467	)			(10,446	)
Purchase of current and non-current financial assets							(2,115,712	)			—
Proceeds from sale of current financial assets							8,263,658				17,666,078
Net cash from / (used in) investing activities							6,138,480				17,655,632
Financing activities
Proceeds from issuance of ordinary shares							—				16,143,686
Proceeds from pre-funded warrants							—				12,915,909
Transaction costs from issuance of ordinary shares and pre-funded warrants							—				(1,949,998	)
Repayment of lease liabilities							(74,690	)			(100,097	)
Net cash from / (used in) financing activities							(74,690	)			27,009,500
Net increase/decrease in cash and cash equivalents							(1,328,555	)			30,649,459
Effect of exchange rate changes on cash and cash equivalents							300,176				(1,738,808	)
Cash and cash equivalents at beginning of period							16,022,171				18,375,979
Cash and cash equivalents at end of period			14				14,993,792				47,286,630

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-6

InflaRx N.V. and subsidiaries

Notes to the unaudited condensed consolidated financial statements

1. Summary of significant accounting policies and other disclosures

a) Reporting entity and the Group’s structure

InflaRx N.V. (the “Company” or “InflaRx”) is a Dutch public company with limited liability (naamloze vennootschap) with its corporate seat in Amsterdam, the Netherlands, and is registered in the Commercial Register of the Netherlands Chamber of Commerce Business Register under CCI number 68904312. The Company’s registered office is at Winzerlaer Straße 2 in 07745 Jena, Germany. Since November 10, 2017, InflaRx N.V.’s ordinary shares have been listed on the Nasdaq Global Select Market under the symbol IFRX.

InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system by focusing on applying its proprietary anti-C5a and C5aR technologies to discover, develop and commercialize first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. These consolidated financial statements of InflaRx comprise the Group.

b) Basis of preparation

These interim condensed consolidated financial statements for the three-month periods ended March 31, 2026, and 2025 have been prepared in accordance with IAS 34 Interim Financial Reporting. These condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements. The condensed consolidated financial statements require management to make judgments, estimates and assumptions which are the same as at year end. Estimates and underlying assumptions are reviewed on an ongoing basis. Accordingly, this report is to be read in conjunction with the financial statements in the Company’s annual report for the year ended December 31, 2025 on Form 20–F.

These consolidated financial statements have been prepared on the basis that the group will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of the business. The Group expects to incur operating losses for the foreseeable future due to, among other things, costs related to the continued advancement of its clinical programs and the operation of its administrative organization. As a result, a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern and, therefore, the Group may be unable to realize its assets and discharge its liabilities in the normal course of business. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements in the Company’s annual report for the year ended December 31, 2025 on Form 20–F.

The Group’s primary sources of funds are proceeds from the sale of its shares including the initial public offering, following offerings and government grants.

The interim condensed consolidated financial statements were authorized for issue by the board of directors of the Company (the “Board of Directors”) on May 6, 2026.

The financial statements are presented in euros (€). The euro is the functional currency of InflaRx N.V. and InflaRx GmbH. The functional currency of InflaRx Pharmaceuticals Inc. is the U.S. dollar.

All financial information presented in euros have been rounded to the nearest euro. Accordingly, numerical figures shown as totals in some tables may not be an arithmetic aggregation of the figures that precede them or may deviate from other tables.

The accounting policies adopted are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2025, except for the adoption of new standards effective as of January 1, 2026, as set out below. The Group has not adopted any other standard, interpretation or amendment that has been issued but is not yet effective early.

The following amendments were adopted effective January 1, 2026, and do not have a material impact on the consolidated financial statements of the Group:

• Amendments to IAS 21 Effects of Changes in Foreign Exchange Rates: Lack of exchangeability

F-7

The following standards issued will be adopted in a future period, and the potential impact, if any, they will have on the Group’s consolidated financial statements is being assessed:

• Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, Classification and Measurement of Financial Instruments

• Amendments to IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures, Contracts Referencing Nature-dependent Electricity

• IFRS 18 Presentation and Disclosure in Financial Statements

• Annual Improvements Volume 11

On January 8, 2026, InflaRx announced a restructuring and a change in strategy, focusing future resource allocation predominantly towards further clinical development of izicopan. As part of this strategy, a significant reduction of its workforce was announced, predominantly in areas which were supporting commercialization and late-stage development of vilobelimab. These measures, including write-down of product inventory and one-time restructuring cost already reflected in the 2025 financial statements and additional one-time restructuring costs of €0.6 million in the three months ended March 31, 2026, once successfully implemented, are expected to reduce the future cost structure of the Company.

2. Revenues

For both the three months ended March 31, 2026 and the three months ended March 31, 2025, the Company did not generate any revenue. For 2026, this is attributable to the Company’s discontinuation of GOHIBIC (vilobelimab) sales activities in the United States in December 2025.

3. Cost of sales

During the three months ended March 31, 2026, the Group incurred €0.0 thousand (2025: €9.3 thousand) of cost of sales. The fact that no cost of sales were incurred in the three months ended March 31, 2026 is attributable to the discontinuation of our sales activities in December 2025.

4. Sales and marketing expenses

During the three months ended March 31, 2026, the Group incurred €0.1 million (2025: €1.5 million) of sales and marketing expenses in the United States. This decrease of €1.4 million is attributable to the discontinuation of sales activities at the end of 2025. The expenses of €0.1 million during the three months ended March 31, 2026 relate to processing costs associated with closing down sales operations.

5. Research and development expenses

During the three months ended March 31, 2026, the Group incurred €4.2 million (2025: €7.0 million) of research and development expenses. These expenses are mainly composed of €2.0 million (2025: €2.7 million) in personnel costs due to lower share-based payment expense and €1.9 million (2025: €4.0 million) in external services for the Group’s research and development projects. Restructuring expenses in the amount of €0.4 million incurred during the three months ended March 31, 2026 for employee-related expenses.

6. General and administrative expenses

During the three months ended March 31, 2026, the Group incurred €3.2 million (2025: €5.1 million) of general and administrative expenses. These expenses are mainly composed of €1.8 million (2025: €2.6 million) in personnel costs due to lower share-based payment expense, €0.6 million (2025: €1.0 million) in legal, consulting and audit fees, €0.8 million (2025: €1.5 million) in other general and administrative expenses. Restructuring expenses in the amount of €0.2 million were incurred during the three months ended March 31, 2026 for employee-related expenses.

7. Other income

Other income for the three months ended March 31, 2026 amounted to €0.2 million (2025: €0.5 million) and primarily relates to research allowances recognized in connection with eligible research and development expenditures incurred during the period.

F-8

8. Net financial result

		For the three months ended March 31,
		2026 (unaudited)				2025 (unaudited)
						(in €)
Interest income			334,768				493,764
Interest expenses			—				(443	)
Interest on lease liabilities			(14,809	)			(3,643	)
Financial result			319,959				489,678
Foreign exchange income			764,782				1,229,009
Foreign exchange expense			(272,400	)			(3,137,838	)
Foreign exchange result			492,382				(1,908,829	)
Result of expected credit loss adjustment on marketable securities			—				—
Result from the revaluation of pre-funded warrants at fair value			803,160				6,110,264
Other financial result			803,160				6,110,264
Net financial result			1,615,501				4,691,112

For the three months ended March 31, 2026, the net financial result decreased by €3.1 million to a gain of €1.6 million, compared with a gain of €4.7 million for the three months ended March 31, 2025. The decrease is mainly attributable to a €5.3 million lower fair value adjustment of pre-funded warrants issued in February 2025, partially offset by a €2.4 million improvement in foreign exchange results due to a short-term weakening of the U.S. dollar.

9. Inventory

As of March 31, 2026 and December 31, 2025, inventory amounted to €0.0 million. As part of its strategic refocusing, the Group discontinued GOHIBIC (vilobelimab) commercial activities and related functions in the United States. Due to this discontinuation, inventory has been fully written down.

10. Other assets

		As of March 31, 2026 (unaudited)				As of December 31, 2025
		(in €)
Non-current other assets
Prepaid expenses			139,192				151,198
Total non-current other assets			139,192				151,198
Current other assets
Prepayments on research & development projects			2,252,867				2,222,380
Prepaid expenses			788,585				923,832
Others			172,321				114,826
Total current other assets			3,213,773				3,261,038
Other assets from research allowances
Current other assets from research allowances			2,732,817				2,487,763
Total other assets from research allowances			2,732,817				2,487,763
Total other assets			6,085,783				5,899,999

F-9

As of March 31, 2026, prepayments on research and development projects amounted to €2.3 million compared to €2.2 million as of December 31, 2025, and consist of prepayments on CRO contracts.

Prepaid expenses consist mainly of prepaid D&O insurance expense for the year 2026, which will be recognized into general and administrative expenses pro rata over the year.

As of March 31, 2026, other assets from research allowances were €2.7 million compared to  €2.5 million as of December 31, 2025, which represent reimbursements the Company qualifies for under the German Research Allowance Act (government grant). The increase is due to additional receivables recognized for eligible expenses incurred in the three months ended March 31, 2026 in the amount of €0.2 million.

11. Tax receivables

As of March 31, 2026, tax receivables amounted to €1.7 million (VAT: €0.5 million, income tax receivables: €1.2 million) compared to €1.4 million (VAT: €0.3 million, income tax receivables: €1.1 million) as of December 31, 2025.

12. Financial assets and financial liabilities

Set out below is an overview of financial assets and liabilities, other than cash and cash equivalents, held by the Group as of March 31, 2026 and December 31, 2025:

		As of March 31, 2026 (unaudited)				As of December 31, 2025
		(in €)
Financial assets at amortized cost
Non-current financial assets			237,459				237,373
Thereof marketable securities			—				—
Current financial assets			24,806,894				30,435,088
Thereof marketable securities			24,690,348				30,211,169
Financial liabilities at amortized cost
Trade and other payables			5,057,588				5,608,204
Financial liabilities at fair value
Current liabilities to shareholders			5,250,652				5,802,128

In February 2025, the Company issued 6,750,000 pre-funded warrants to certain investors in the context of a public offering of securities. As of March 31, 2026, the fair value of the warrants amounted to €5.3 million (Level 1).

As of March 31, 2026, the fair value of current and non-current financial assets (primarily quoted debt securities) amounted to €25.0 million (as of December 31, 2025: €33.5 million) (Level 1). The Group’s debt instruments at amortized cost consist solely of quoted securities that are graded highly by credit rating agencies such as S&P Global and, therefore, are considered low credit risk investments.

As of March 31, 2026, current and non-current financial assets decreased by €5.6 million to  €25.0 million compared to  €30.7 million of December 31, 2025. The decrease is mainly due to the financing of day-to-day operations. As of March 31, 2026, trade and other payables decreased by €0.6 million to €5.1 million compared to €5.6 million as of December 31, 2025. As of December 31, 2025 the Company temporarily had higher trade payables from CROs.

F-10

13. Trade payables and other accrued liabilities

		As of March 31, 2026 (unaudited)				As of December 31, 2025
		(in €)
Accrued liabilities from R&D projects			3,375,492				3,424,362
Accrued liabilities from commercial activities			—				8,000
Accounts payable			366,679				972,383
Other accrued liabilities and payables			1,490,905				1,353,593
Total			5,233,077				5,758,338

Accrued liabilities from R&D projects include third party services from the Company’s ongoing R&D projects that have not yet been invoiced to the Company as of the reporting date.

14. Cash and cash equivalents

		As of March 31, 2026 (unaudited)				As of December 31, 2025
		(in €)
Short-term deposits
Deposits held in U.S. dollars			1,574,317				7,510,452
Deposits held in euros			6,620,000				7,235,080
Total			8,194,317				14,745,532
Cash at banks
Cash held in U.S. dollars			6,094,726				843,915
Cash held in euros			704,749				432,724
Total			6,799,475				1,276,639
Total cash and cash equivalents			14,993,792				16,022,171

As of March 31, 2026, cash and cash equivalents decreased by €1.0 million to €15.0 million compared to €16.0 million as of December 31, 2025.

15. Equity

On June 30, 2023, the Company filed a Form F-3, or the 2023-Registration Statement, with the Securities Exchange Commission, or the SEC, with respect to the offer and sale of securities of the Company, which became effective on July 11, 2023. The aggregate initial offering price of the securities that the Company may offer and sell under this prospectus will not exceed $250.0 million. In 2024, the Company subsequently filed a prospectus supplement with the SEC relating to an at-the-market program providing for the sale of up to $75.0 million of our ordinary shares over time pursuant to a sales agreement with Leerink Partners LLC, or the Sales Agreement.

We did not issue any ordinary shares under the 2023-Registration Statement in the first quarter of 2026.

In 2025, we issued 4,691,149 ordinary shares under the Sales Agreement, resulting in € 6.9 million ($8.0 million) in net proceeds. As of December 31, 2025 and March 31, 2026, the remaining value authorized for sale under the Sales Agreement amounted to $65.7 million.

In February 2025, the Company completed an underwritten public offering of 8,250,000 ordinary shares at a public offering price of $2.00 per ordinary share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 6,750,000 ordinary shares. The public offering price for each pre-funded warrant was equal to the price per share at which the ordinary shares were sold to the public, minus $0.001, which is the exercise price of each pre-funded warrant. The warrants are only exercisable by cashless exercise; the amount of ordinary shares to be received upon cashless exercise of such warrants is dependent on the Company’s market share price at the time of exercise. The net proceeds from the offering were €26.8 million ($28.0 million). The warrants have an indefinite expiration and are fully or partly exercisable at any time.

F-11

16. Share-based payments

a) Equity settled share-based payment arrangements

InflaRx GmbH granted options under the 2012 Stock Option Plan. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. at the time of its IPO in November 2017:

Number of share options		2026				2025
Outstanding as of January 1,			148,433				148,433
Exercised during the three months ended March 31,			—				—
Outstanding as of March 31,			148,433				148,433
thereof vested / exercisable			148,433				148,433

Under the terms and conditions of the share option plan 2016, InflaRx GmbH granted rights to subscribe for InflaRx GmbH’s ordinary shares to directors, senior management, and key employees. Those InflaRx GmbH options were converted into options for ordinary shares of InflaRx N.V. at the time of its IPO in November 2017:

Number of share options		2026				2025
Outstanding as of January 1,			888,632				888,632
Exercised during the three months ended March 31,			—				—
Outstanding as of March 31,			888,632				888,632
thereof vested / exercisable			888,632				888,632

InflaRx also granted share options under the 2017 Long-Term Incentive Plan, or 2017 LTIP, subsequently to its IPO in November 2017. The total number of share options granted during the three months ended March 31, 2026 under the 2017 LTIP was as follows:

Number of share options		2026				2025
Outstanding as of January 1,			11,122,320				8,905,446
Granted during the three months ended March 31,			2,828,925				2,452,000
Expired during the three months ended March 31,			—				(98,876	)
Forfeited during the three months ended March 31,			(25,000	)			(136,250	)
Outstanding as of March 31,			13,926,245				11,122,320
thereof vested / exercisable			11,097,320				10,505,820

The key information and assumptions related to share options granted during the three months ended March 31, 2026 under the 2017 LTIP were as follows:

Share options granted 2026		Number		Fair value per option		FX rate as of grant date		Fair value per option		Share price at grant date / Exercise price		Expected volatility		Expected life (midpoint based)		Risk-free rate (interpola ted, U.S. sovereign strips curve)
January 06		2,373,975		$0.930		0.8542		0.790 €		$1.17		1.02		5.50		3.772%
January 06		454,950		$0.796		0.8542		0.680 €		$1.17		1.02		5.49		3.771%
		2,828,925

F-12

Of the 2,828,925 options granted in the three months ended March 31, 2026 (ended March 31, 2025: 2,452,000), 2,136,450 options (March 31, 2025: 1,700,000) were granted to members of the executive management or Board of Directors. From these options 454,950 options were granted as performance options (March 31, 2025: 0). The awards are subject to two independent performance conditions, each covering 50% of the grant. The funding condition is a non-market condition valued using Black-Scholes, with expected vesting adjusted for probability. The share price condition is a market condition valued using a Monte Carlo simulation, with the probability embedded in fair value. Each tranche vests separately, with cliff vesting on December 31, 2026.

Expected dividends are nil for all share options listed above.

b) Share-based payment expense recognized

For the three months ended March 31, 2026, the Company has recognized €0.9 million of share-based payment expense in the 2026 statements of operations and comprehensive loss.

For the three months ended March 31, 2025, the Company has recognized €2.5 million of share-based payment expense in the statements of operations and comprehensive loss including €356 thousand for the extension of option for the eight-year option terms to ten years.

None of the share-based payment awards were dilutive in determining earnings per share due to the Group’s loss position.

c) Share options exercised

During the three months ended March 31, 2026, no shares (2025: nil) were issued upon the exercise of share options, resulting in no proceeds to the Company (ended March 31, 2025: nil).

17. Protective foundation

According to the articles of association of the Company, up to 169,300,000 ordinary shares and up to 169,300,000 preferred shares with a nominal value of €0.12 per share are authorized to be issued. All shares are registered shares. No share certificates shall be issued.

In order to deter acquisition bids, the Company’s general meeting of shareholders approved the right of an independent foundation under Dutch law, or protective foundation, to exercise a call option pursuant to the call option agreement, upon which preferred shares will be issued by the Company to the protective foundation of up to 100% of the Company’s issued capital held by others than the protective foundation, minus one share. The protective foundation is expected to enter into a finance arrangement with a bank or, subject to applicable restrictions under Dutch law, the protective foundation may request the Company to provide, or cause the Company’s subsidiaries to provide, sufficient funding to the protective foundation to enable it to satisfy its payment obligation under the call option agreement.

These preferred shares will have both a liquidation and dividend preference over the Company’s ordinary shares and will accrue cash dividends at a pre-determined rate. The protective foundation would be expected to require the Company to cancel its preferred shares once the perceived threat to the Company and its stakeholders has been removed or sufficiently mitigated or neutralized. The Company believes that the call option does not represent a significant fair value based on a level 3 valuation since the preferred shares are restricted in use and can be cancelled by the Company.

During the three months ended March 31, 2026, the Company expensed €11.0 thousand (2025: €15.0 thousand) of ongoing costs to reimburse expenses incurred by the protective foundation.

18. Subsequent events

There were no subsequent events requiring disclosure through May 6, 2026, the date these interim condensed consolidated financial statements were authorized for issue.

 F-13

Exhibit 99.2

MANAGEMENT’S DISCUSSION AND ANALYSIS

OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis is designed to provide you with a narrative explanation of our financial condition and results of operations. We recommend that you read this discussion together with our unaudited interim condensed consolidated financial statements, including the notes thereto, for the three months ended March 31, 2026 and 2025, respectively, included as Exhibit 99.1 to the report on Form 6-K to which this discussion is attached as Exhibit 99.2. We also recommend that you read our “ITEM 5. Operating and financial review and prospects” and our audited consolidated financial statements for fiscal year 2025, and the notes thereto, which appear in our annual report on Form 20-F for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission, or the SEC, on March 20, 2026. In addition, we recommend that you read any public announcements made by InflaRx N.V.

The following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB, which may differ in material respects from generally accepted accounting principles in the United States and other jurisdictions. We maintain our books and records in euros. Unless otherwise indicated, all references to currency amounts in this discussion are in euros. We have made rounding adjustments to some of the figures included in this discussion and analysis. Accordingly, numerical figures shown as totals in some tables may not be arithmetic aggregations of the figures that precede them.

The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including but not limited to those described under “ITEM 3. Key Information––Risk factors” in the annual report and risks described in our subsequent SEC filings.

Unless otherwise indicated or the context otherwise requires, all references to “InflaRx” or the “Company,” “we,” “our,” “ours,” “us” or similar terms refer to InflaRx N.V. and its subsidiaries InflaRx GmbH and InflaRx Pharmaceuticals, Inc.

Overview

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx is developing izicopan (formerly known as INF904), a novel orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor. InflaRx has also developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

Dr. Camilla Chong will resign from her position as Chief Medical Officer, effective August 2026. Her resignation did not result from any disagreement with the Company regarding its operations, policies, or clinical development programs. The Company’s existing clinical team and senior management, supported by external advisors, are overseeing her responsibilities to ensure continuity across the Company’s clinical development activities.

On January 8, 2026, InflaRx announced a restructuring and a change in strategy, focusing future resource allocation predominantly towards further clinical development of izicopan. As part of this strategy, a significant reduction of its workforce was announced, predominantly in areas which were supporting commercialization and late-stage development of vilobelimab. These measures, including write-down of product inventory and one-time restructuring cost already reflected in the 2025 financial statements and additional one-time restructuring costs of €0.6 million in 2026, once successfully implemented, are expected to reduce the future cost structure of the Company.

1

Anti-C5aR inhibitor izicopan

To explore the full potential of our anti-C5a/C5aR technologies, we are clinically developing our lead product candidate, izicopan, which is an orally administered, small-molecule inhibitor of C5aR1. Based on its mode of action and encouraging preclinical and clinical data generated to date, we believe izicopan is a promising product candidate for being further developed in several disease areas of inflammation, where orally available therapeutics are not available or do not meet the medical need.

Izicopan has shown potential for superior characteristics to the only approved C5aR inhibitor, avacopan, in pre-clinical studies and in clinical pharmacology studies. Izicopan has demonstrated higher plasma exposure in animals, including non-human primates, and humans. Izicopan is also characterized by an improved inhibitory activity in a hamster neutropenia model compared to avacopan and in our completed pharmacodynamic Phase 1 studies. As announced in April 2026, in vitro findings demonstrate that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity. In addition, izicopan demonstrated potential for anti-inflammatory therapeutic effects in several preclinical disease models. In January 2024, we announced the positive results of a single and multiple ascending dose study with izicopan in healthy volunteers. In November 2025, we reported positive data from a Phase 2a clinical study in HS and CSU patients.

Izicopan for the treatment of HS

HS is a chronic, recurrent, debilitating neutrophil-driven inflammatory skin disease that can persist for years and is severely debilitating and tremendously impacts quality of life. It is characterized by three types of skin lesions: abscesses, nodules and draining tunnels. Izicopan inhibits the known C5a-induced effects on neutrophil activation and tissue accumulation of immune cells, including generation of tissue damaging mechanisms (enzyme release and oxidative radical formation) as well as induction of NETosis – mechanisms thought to be involved in HS progression and draining tunnel formation. Clinical evidence with existing C5a/C5aR products also supports that blocking this pathway reduces lesion counts. Patients’ responses to treatment with currently approved anti-TNF-alpha or anti-IL17 drugs are known to wane over time in a significant number of cases; and treatment with new therapeutics acting through other molecular mechanisms are needed for these patients. In our recently concluded Phase 2a clinical study we could gather strong evidence that izicopan is highly active in HS, with improvements in efficacy measures largely differentiated from historically reported placebo response rates, and in line with reported improvements at the 4-week time point for therapies which have successfully completed Phase 3 trials or received approval. Given this positive, biologic-like emerging clinical profile, with rapid, consistent and significant reductions in all lesion counts, total inflammatory burden (TIB), and patient reported outcomes (in particular NRS30 Skin Pain), we are progressing our plans for further clinical development.

Izicopan for the treatment of AAV and other renal diseases

Given the role of the C5a/C5aR axis in AAV, support from key opinion leaders, and recent developments in the commercial market, InflaRx intends to pursue development with izicopan in this indication. In addition, the Company intends to establish proof-of-concept for izicopan across a broader range of kidney diseases, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), and C3 glomerulopathy (C3G).

Izicopan for the treatment of CSU

CSU is a debilitating and unpredictable skin disease, characterized by intensely itchy hives / wheals and angioedema. The burden of this chronic disease is high and impacts sleep, mental health, quality of life and productivity due to absences from school and work. CSU is estimated to affect around 40 million people worldwide. CSU patients have been reported to show elevated C5a levels, a major activator of mast cells and basophils which are thought to be significant contributors to CSU pathogenesis. In addition, studies suggest that complement activation (including through C5a) in CSU can lead to histamine release. Current treatments for patients that do not respond to readily available anti-histamines are limited, and a significant unmet need exists in a sizable proportion of patients. In our recently concluded Phase 2a clinical study we could show encouraging data in these patients, suggesting that izicopan is active in CSU and not only differentiated from reported historical placebo rates, but potentially within the range of currently approved CSU therapies. These data further indicate that response rates may deepen with longer-term treatment. Given this positive emerging clinical profile, we are planning further development potentially in collaboration with pharmaceutical partners.

2

Anti-C5a antibody vilobelimab

Vilobelimab, is a novel, intravenously delivered, first-in-class monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings. We have been developing vilobelimab in a wide array of complement-mediated diseases with significant unmet medical need.

Vilobelimab for the treatment of severe COVID-19

Vilobelimab has been tested in critically ill COVID-19 patients, for which we concluded a double-blinded, placebo controlled, multicenter Phase 3 study in March 2022, demonstrating a relative reduction in 28-day all-cause mortality by 23.9%. Subsequently, in April 2023, we were granted an EUA by the FDA for the treatment of critically ill, invasively mechanically ventilated COVID-19 patients. In January 2025, we obtained a marketing authorization under exceptional circumstances, by the European Commission for the treatment of adult patients with SARS-CoV-2-induced ARDS, who are receiving systemic corticosteroids as part of standard of care and receiving invasive mechanical ventilation, or IMV, with or without extracorporeal membrane oxygenation, or ECMO. The product has been introduced into the pharmaceutical market in the U.S. under the tradename GOHIBIC and is commercially available for ordering by hospitals. Vilobelimab is also being evaluated in a Phase 2 clinical platform study in broader ARDS, funded by the Biomedical Advanced Research and Development Authority, or BARDA.

Anti-C5a antibody IFX002

We are developing IFX002 for the treatment of chronic inflammatory diseases. IFX002 is a highly potent anti- C5a antibody, which binds to the same domain of the C5a protein as vilobelimab, but which has a higher humanization grade and altered pharmacokinetic properties compared to vilobelimab. IFX002 is currently in preclinical development. We consider IFX002 to be a life-cycle management product to vilobelimab, given the long remaining patent life of IFX002.

Financial highlights

As of March 31, 2026, we had available funds amounting to €39.7 million, composed of €15.0 million in cash and cash equivalents and €24.7 million in marketable securities. Of the €15.0 million cash and cash equivalents, €7.3 million are held in euros and €7.7 million are held in U.S. dollars. Marketable securities held in U.S. dollars have a nominal value of $28.5 million (€24.8 million). We believe that our current funds on hand will be sufficient to fund our planned operations into 2027.

We anticipate that our expenses might increase if and as we:

• continue research, preclinical and clinical development efforts, as applicable, for any existing and future product candidates, including izicopan, vilobelimab and IFX002;

• actively seek to identify additional research programs and additional product candidates;

• seek regulatory and marketing approvals for our product candidates that successfully complete clinical trials, if any;

• establish and expand sales, marketing, distribution and other commercial infrastructure now and in the future to commercialize various products for which we may obtain marketing authorization or approval, if any;

• require the scale-up and validation of the manufacturing process and the manufacturing of larger quantities of product candidates for clinical development and, potentially, commercialization;

• collaborate with strategic partners to optimize the manufacturing process for izicopan, vilobelimab, IFX002, and other pipeline products;

• maintain, expand and protect our intellectual property portfolio;

• hire and retain additional personnel, such as commercial, marketing, clinical, quality control and scientific personnel; and

3

• add operational, financial and management information systems and personnel, including personnel to support our product development as well as commercialization and help us comply with our obligations as a public company.

Our ability to become and remain profitable depends on our ability to generate revenue. We do not expect to generate significant revenue unless and until we are, or any future collaborator is, able to obtain full marketing authorization or approval for, and successfully commercialize, one or more of our product candidates. Successful commercialization will require achievement of key milestones, including completing clinical trials of izicopan, vilobelimab, and any other product candidates, obtaining marketing authorization or approval for these product candidates, manufacturing, marketing and selling those products for which we, or any of our future collaborators, may obtain marketing authorization or approval, satisfying any post-marketing requirements and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated with these activities, we are unable to accurately predict the timing and amount of revenues, and if or when we might achieve profitability. We and any future collaborators may never succeed in these activities and, even if we do, or any future collaborators do, we may never generate revenue that is large enough for us to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

We expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. In order to succeed, we will need to transition from a company with a research and development focus to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and delays, and may not be successful in such a transition.

Accordingly, we may seek to further fund our operations through public or private equity or debt financings or other sources, including strategic collaborations. We may, however, be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements as and when needed would have a negative impact on our financial condition and our ability to develop vilobelimab or any additional product candidates.

Our failure to become and remain profitable could depress the market price of our ordinary shares and could impair our ability to raise capital, pay dividends, expand our business, diversify our product offerings or continue our operations. If we continue to suffer losses as we have in the past, investors may not receive any return on their investment and may lose their entire investment.

Research and development expenses

Research and development expenses have consisted principally of:

• expenses incurred under agreements with CROs, contract manufacturing organizations, or CDMOs, consultants and independent contractors that conduct research and development, preclinical and clinical activities on our behalf;

• employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization; and

• professional fees for lawyers related to the protection and maintenance of our intellectual property.

We expense research and development costs as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as status of patient enrollment or clinical site activations for measuring services received and efforts expended. Research and development activities are central to our business model.

Our research and development expenses primarily relate to the following key programs:

• Vilobelimab. Our expenses associated with vilobelimab have decreased significantly as a result of the January 2026 restructuring and the termination of our Phase 3 study in PG. We expect vilobelimab-related expenses to continue to decrease in 2026 compared to 2025. However, we will still incur costs associated with the wind-down of the Phase 3 trial in PG, ongoing participation in the BARDA-sponsored Phase 2 clinical platform study in broader ARDS, maintaining our manufacturing infrastructure for GOHIBIC (vilobelimab) in compliance with regulatory standards, and continued FDA discussions regarding a potential BLA for full approval of GOHIBIC (vilobelimab). Any future clinical development activities in PG or other indications would likely be conducted only in collaboration with a partner

4

• Izicopan. We are developing izicopan, a product candidate that targets C5aR. We expect to incur additional costs by advancing the clinical and non-clinical development of izicopan. Specifically, we expect to incur expenses during Phase 2 clinical development. We plan to continue studying izicopan in complement-mediated, chronic autoimmune and inflammatory conditions where an oral low molecular weight compound might have advantages or is needed for patients and where oral delivery is the medically preferred route of administration.

• IFX002. We are developing IFX002 for the treatment of chronic inflammatory indications. IFX002 is a highly potent anti-complement C5a antibody with a higher humanization grade and altered PK properties compared to vilobelimab and is currently in pre-clinical development. Expenses for this program mainly consist of salaries, costs for preclinical testing conducted by CROs and costs to produce preclinical material.

• Other development programs. Our other research and development expenses relate to our preclinical studies of other product candidates and discovery activities, expenses for which mainly consist of salaries, costs for production of preclinical compounds and costs paid to CROs.

General and administrative expenses

Our general and administrative expenses consist principally of:

• employee-related expenses, including salaries, benefits and stock-based compensation expense based upon employees’ role within the organization;

• professional fees for auditors and consulting expenses not related to research and development activities;

• professional fees for lawyers not related to the filing, prosecution, protection and maintenance of our intellectual property;

• insurance expenses including directors and officers liability insurance premiums; and

• cost of facilities, travel, communication and office expenses.

5

Results of operations

The information below was derived from our unaudited interim condensed consolidated financial statements included elsewhere herein. The discussion below should be read along with these unaudited interim condensed consolidated financial statements and our Annual Report.

Comparison of the three months ended March 31, 2026 and 2025

		three months ended March 31,
		2026				2025				Change
		(in €)
Revenues			—				—				—
Cost of sales			—				(9,291	)			9,291
Gross profit			—				(9,291	)			9,291
Operating expenses
Sales and marketing expenses			(108,072	)			(1,457,978	)			1,349,906
Research and development expenses			(4,170,546	)			(7,016,336	)			2,845,791
General and administrative expenses			(3,177,444	)			(5,062,605	)			1,885,160
Total operating expenses			(7,456,062	)			(13,536,919	)			6,080,857
Other income			247,978				541,098				(293,119	)
Other expenses			(66	)			(26	)			(40	)
Operating result			(7,208,150	)			(13,005,139	)			5,796,989
Finance income			334,768				493,764				(158,996	)
Finance expenses			(14,809	)			(4,086	)			(10,723	)
Foreign exchange result			492,382				(1,908,829	)			2,401,212
Other financial result			803,160				6,110,264				(5,307,103	)
Income taxes			—				—				—
Income (loss) for the period			(5,592,649	)			(8,314,027	)			2,721,378
Exchange differences on translation of foreign currency			(15,026	)			(150,667	)			135,640
Total comprehensive income (loss)			(5,607,675	)			(8,464,694	)			2,857,018

Revenues

For both the three months ended March 31, 2026 and the three months ended March 31, 2025, we did not generate any revenue. For 2026, this is attributable to the discontinuation of GOHIBIC (vilobelimab) sales activities in the United States in December 2025.

Cost of sales

		three months ended March 31,
		2026				2025				Change
		(in €)
Cost of sales			—				9,291				(9,291	)
Total			—				9,291				(9,291	)

The fact that we incurred no cost of sales in the three months ended March 31, 2026 is attributable to the discontinuation of our sales activities in December 2025.

6

Sales and marketing expenses

		three months ended March 31,
		2026				2025				Change
		(in €)
Third-party expenses			36,610				207,811				(171,201	)
Marketing expenses			3,082				205,078				(201,996	)
Personnel expenses			54,247				644,216				(589,970	)
Legal and consulting fees			10,155				261,332				(251,178	)
Other expenses			3,978				139,541				(135,562	)
Total sales and marketing expenses			108,072				1,457,978				(1,349,906	)

Our sales and marketing expenses incurred for the three months ended March 31, 2026 decreased compared to the three months ended March 31, 2025 by €1.3 million to €0.1 million. This decrease is attributable to the discontinuation of our sales activities at the end of 2025.

The expenses of €0.1 million during the three months ended March 31, 2026 relate to processing costs associated with closing down sales operations.

Research and development expenses

		three months ended March 31,
		2026				2025				Change
		(in €)
Third-party expenses			1,885,957				3,969,044				(2,083,087	)
thereof vilobelimab			460,581				1,559,909				(1,099,328	)
thereof izicopan			1,334,073				2,340,564				(1,006,491	)
thereof non-allocated			91,303				68,571				22,732
Personnel expenses			1,964,384				2,678,658				(714,274	)
Other expenses			320,205				368,634				(48,429	)
thereof vilobelimab			113,822				120,189				(6,367	)
thereof izicopan			173,404				46,367				127,037
thereof non-allocated			32,979				202,078				(169,099	)
Total research and development expenses			4,170,546				7,016,336				(2,845,791	)

Our research and development expenses incurred for the three months ended March 31, 2026 decreased by €2.8 million to €4.2 million compared to the three months ended March 31, 2025. This decrease is primarily due to lower third-party expenses for external services for the Group’s research and development projects, as well as lower personnel expenses due to reduced share-based payment expenses. The year‑over‑year decrease in third‑party expenses primarily reflects that, during the three months ended March 31, 2025, our PG study was still ongoing and continued to incur related costs.

General and administrative expenses

		three months ended March 31,
		2026				2025				Change
		(in €)
Personnel expenses			1,828,964				2,628,711				(799,747	)
Legal, consulting and audit fees			588,528				969,883				(381,355	)
Other expenses			759,952				1,464,011				(704,059	)
Total general and administrative expenses			3,177,444				5,062,605				(1,885,160	)

Our general and administrative expenses incurred for the three months ended March 31, 2026 decreased by €1.9 million to €3.2 million compared to the three months ended March 31, 2025. This decrease is primarily due to lower personnel expenses, including reduced share-based payment expenses and lower legal and consulting fees.

7

Other income

		three months ended March 31,
		2026				2025				Change
		(in €)
Other income from government grants and research allowances			245,055				532,860				(287,805	)
Further other income			2,924				8,238				(5,315	)
Total other income			247,978				541,098				(293,120	)

Our other income for the three months ended March 31, 2026 decreased by €0.3 million compared to the three months ended March 31, 2025 and primarily consists of research allowances under the “Forschungszulagengesetz” (Research Allowance Act) for the three months ended March 31, 2026.

Net financial result

		three months ended March 31,
		2026				2025				Change
		(in €)
Interest income			334,768				493,764				(158,996	)
Interest expenses			—				(443	)			443
Interest on lease liabilities			(14,809	)			(3,643	)			(11,166	)
Financial Result			319,959				489,678				(169,719	)
Foreign exchange income			764,782				1,229,009				(464,227	)
Foreign exchange expense			(272,400	)			(3,137,838	)			2,865,438
Foreign exchange result			492,382				(1,908,829	)			2,401,212
Result from the revaluation of pre-funded warrants at fair value			803,160				6,110,264				(5,307,103	)
Other financial result			803,160				6,110,264				(5,307,103	)
Net financial result			1,615,501				4,691,112				(3,075,611	)

For the three months ended March 31, 2026, our net financial result decreased by €3.1 million to a gain of €1.6 million from a gain of €4.7 million for the three months ended March 31, 2025. This decrease is mainly attributable to the fair value remeasurement of pre-funded warrants issued in February 2025 in the amount of €5.3 million. This is partially offset by a €2.4 million improvement in foreign exchange results due to a short-term weakening of the U.S. dollar.

Liquidity and capital resources

Since inception, we have incurred significant operating losses. For the three months ended March 31, 2026, we incurred a net loss of €5.6 million. To date, we have financed our operations primarily through the sale of our securities. As of March 31, 2026, we had cash and cash equivalents in the amount of  €15.0 million and financial assets in the amount of €25.0 million, comprised of marketable securities in the amount of €24.7 million and other financial assets amounting to €0.3 million. Our cash and cash equivalents primarily consist of bank deposit accounts and fixed U.S. dollar term deposits.

8

Cash flows

The table below summarizes our consolidated statement of cash flows for the three months ended March 31, 2026 and 2025:

		three months ended March 31,
		2026				2025
		(in €)
Net cash used in operating activities			(7,392,345	)			(14,015,672	)
Net cash from/ (used in) investing activities			6,138,480				17,655,632
Net cash from/ (used in) financing activities			(74,690	)			27,009,500
Cash and cash equivalents at the beginning of the period			16,022,171				18,375,979
Effect of Exchange gains/ (losses) on cash and cash equivalents			300,176				(1,738,808	)
Cash and cash equivalents at the end of the period			14,993,792				47,286,630

1. Net cash from/used in operating activities

The use of cash in all periods resulted primarily from our net losses, adjusted for non-cash charges and changes in components of working capital. Net cash used in operating activities decreased to €7.4 million in the three months ended March 31, 2026, from €14.0 million in the three months ended March 31, 2025.

2. Net cash from/used in investing activities

Net cash from investing activities decreased by €11.5 million in the three months ended March 31, 2026, mainly due to lower proceeds from maturity of marketable securities in the three months ended March 31, 2026 compared to the three months ended March 31, 2025.

3. Net cash from/used in financing activities

Net cash from financing activities decreased by €27.1 million in the three months ended March 31, 2026, compared to the three months ended March 31, 2025, due to a public offering of ordinary shares and pre-funded warrants in the three months ended March 31, 2025.

Funding requirements

We believe our existing cash and cash equivalents and financial assets will enable us to fund our operating expenses and capital expenditure requirements under our current business plan for at least the next 12 months.

We anticipate our expenses will decrease this year with regard to our ongoing activities. In particular, we anticipate significantly reduced sales and marketing efforts for GOHIBIC (vilobelimab) in the United States. We plan to continue required preclinical studies for izicopan and also to conduct a PK bridging study in China.

Beyond our current ongoing activities, we also plan to continue clinical development of izicopan and to initiate Phase 2b clinical trials in HS for which we will need the FDA to accept our clinical trial design and determine the costs for such a clinical trial, with additional clinical activity possible beyond HS, which would require us to secure additional financial resources and which might increase our expenses in the future.

As a result, these events and conditions indicate that a material uncertainty exists that may cast significant doubt on the Group’s ability to continue as a going concern and, therefore, the Group may be unable to realize its assets and discharge its liabilities in the normal course of business.

If clinical data is supportive, we may seek marketing approval for any product candidates that we successfully develop. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to establishing sales, marketing, distribution and other commercial infrastructure to commercialize such products. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce, or eliminate our research and development programs or future commercialization efforts.

9

Until such time, if ever, that we can generate substantial meaningful product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, royalty-based financings, future collaborations, strategic alliances, licensing arrangements and government grants. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interest of our current shareholders will be diluted, and the terms of these securities may include voting or other rights that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Money received through government grants may require us to provide our product, if approved by regulatory authorities, at unfavorable conditions in such jurisdictions.

At-the-market program

On June 28, 2024, we entered into a Sales Agreement with Leerink Partners LLC, to sell our ordinary shares from time to time through an at-the-market, or ATM, equity offering program of up to $75.0 million.

We did not issue any ordinary shares under the Sales Agreement in the first quarter of 2026.

In 2025, we issued 4,691,149 ordinary shares under the Sales Agreement, resulting in € 6.9 million ($8.0 million) in net proceeds. As of December 31, 2025 and March 31, 2026, the remaining value authorized for sale under the Sales Agreement amounted to $65.7 million.

For more information as to the risks associated with our future funding needs, see “ITEM 3. Key Information––Risk factors” in our Annual Report.

Off-balance sheet arrangements

As of March 31, 2026, and during the periods presented, we did not have any off-balance sheet arrangements other than as described under “ITEM 5. Operating and financial review and prospects—off-balance sheet arrangements” in our Annual Report.

Contractual obligations and commitments

We do not have any, and during the periods presented we did not have any, contractual obligations and commitments other than as described under “ITEM 5. Operating and Financial Review and Prospects—Liquidity and capital resources––Contractual obligations and commitments” in the Annual Report.

Quantitative and qualitative disclosures about market risk

During the three months ended March 31, 2026, there were no significant changes to our quantitative and qualitative disclosures about market risk from those reported in “ITEM 11. Quantitative and Qualitative Disclosures About Market Risk” in the annual report.

Critical judgments and accounting estimates

There have been no material changes to the significant accounting policies and estimates described in “ITEM 5. Operating and Financial Review and Prospects—Critical judgments and accounting estimates” in the annual report.

Critical accounting estimates

There have been no material changes to the significant accounting policies and estimates described in Note B.2. to our consolidated financial statements in the annual report.

Cautionary statement regarding forward looking statements

This discussion contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions intended to identify statements about the future. These statements speak only as of the date of this discussion and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements include, without limitation, statements about the following:

10

• the success of our future clinical trials for vilobelimab’s treatment of other debilitating or life-threatening inflammatory indications, including ARDS;

• the potential strategic transactions or collaborations, including a potential partnership of izicopan, or vilobelimab for PG;

• the success of our future clinical trials for izicopan, and whether such clinical results will reflect results seen in previously conducted preclinical studies and clinical trials;

• the timing, progress and results of preclinical studies and clinical trials of vilobelimab, izicopan and any other product candidates, including for the development of vilobelimab in several indications and other virally induced ARDS, HS and CSU, and statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, the costs of such trials and our research and development programs generally;

• our interactions with and the receptiveness and approval by regulators regarding the results of clinical trials and potential regulatory approval or authorization pathways, including our BLA submission for GOHIBIC (vilobelimab);

• the timing and outcome of any discussions or submission of filings for regulatory approval of vilobelimab, izicopan or any other product candidate, and the timing of and our ability to obtain and maintain full regulatory approval and/or market authorization of vilobelimab or izicopan for any indication;

• our ability to leverage our proprietary anti-C5a and anti-C5aR technologies to discover and develop therapies to treat complement-mediated immunological and inflammatory diseases;

• our ability to protect, maintain and enforce our intellectual property protection for vilobelimab, izicopan and any other product candidates, and the scope of such protection;

• whether the FDA or any comparable foreign regulatory authority will accept or agree with the number, design, size, conduct or implementation of our clinical trials, including any proposed primary or secondary endpoints for such trials;

• the success of our future clinical trials for vilobelimab, izicopan and any other product candidates and whether such clinical results will reflect results seen in previously conducted preclinical studies and clinical trials;

• our expectations regarding the size of the patient populations for, the market opportunity for, the medical need for and clinical utility of vilobelimab, izicopan or any other product candidates, if approved or authorized for commercial use;

• our manufacturing capabilities and strategy, including the scalability and cost of our manufacturing methods and processes and the optimization of our manufacturing methods and processes, and our ability to continue to rely on our existing third-party manufacturers and our ability to engage additional third-party manufacturers for our planned future clinical trials and for commercial supply of any development candidate in the United States  and Europe;

• our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing;

• our ability to defend against liability claims resulting from the testing of our product candidates in the clinic or, if, approved or authorized, any commercial sales;

• if any of our product candidates obtain regulatory approval or authorization, our ability to comply with and satisfy ongoing drug regulatory obligations and continued regulatory overview;

11

• our ability to comply with enacted and future legislation in seeking marketing approval or commercialization;

• our future growth and ability to compete, which depends on our retaining key personnel and recruiting additional qualified personnel;

• our competitive position and the development of and projections relating to our competitors in the development of C5a and C5aR inhibitors and other therapeutic products being developed in similar medical conditions in which vilobelimab, izicopan or any other of our product candidates is being developed or our industry; and

• other risk factors discussed under the “ITEM 3. Key information––Risk factors” section of our Annual Report on Form 20-F.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. You should refer to the “ITEM 3. Key information––Risk factors” section of our Annual Report and risks described in our subsequent SEC filings for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we cannot assure you that the forward-looking statements in this discussion or in our Annual Report will prove to be accurate. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. You should, however, review the factors and risks and other information we describe in the reports we will file from time to time with the SEC after the date of this discussion.

12

FAQ

How did InflaRx (IFRX) perform financially in Q1 2026?

InflaRx reported a Q1 2026 net loss of €5.6 million, improving from €8.3 million a year earlier. Operating expenses fell to €7.5 million as sales, R&D and G&A costs declined following the discontinuation of GOHIBIC commercialization and lower share-based payment expenses.

Did InflaRx (IFRX) generate any revenue in Q1 2026?

No, InflaRx generated no revenue in Q1 2026, the same as in Q1 2025. The company attributes the absence of revenue and cost of sales to the discontinuation of GOHIBIC (vilobelimab) sales activities in the United States in December 2025, reflecting a strategic shift away from commercialization.

What is InflaRx’s cash and funding position as of March 31, 2026?

As of March 31, 2026, InflaRx held €15.0 million in cash and cash equivalents and €24.7 million in marketable securities, totaling about €39.7 million. Management believes these funds will support the current business plan into 2027, assuming execution consistent with its stated strategy.

What restructuring actions did InflaRx (IFRX) take in early 2026?

On January 8, 2026, InflaRx announced a restructuring and strategic shift to focus resources predominantly on clinical development of izicopan. This included a significant workforce reduction in functions supporting vilobelimab commercialization and late-stage development, and €0.6 million of additional one-time restructuring costs in Q1 2026.

Why does InflaRx highlight going concern risks in its Q1 2026 report?

InflaRx states it expects to incur operating losses for the foreseeable future, tied to advancing clinical programs and running its organization. It discloses that these factors create a material uncertainty that may cast significant doubt on its ability to continue as a going concern, despite its current funding runway.

Which drug programs are central to InflaRx’s current strategy?

InflaRx is prioritizing izicopan, an oral C5aR inhibitor, with planned Phase 2b development in hidradenitis suppurativa and broader work in CSU and kidney diseases. Vilobelimab and IFX002 remain in the portfolio, but the resource allocation focus is now predominantly on izicopan’s clinical development.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 495.0 KB
• EX-99.2 EXHIBIT 99.2 241.8 KB